News stories about Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Verona Pharma plc – American Depositary Share earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.69650056273 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities research analysts have recently issued reports on VRNA shares. Berenberg Bank assumed coverage on shares of Verona Pharma plc – American Depositary Share in a research report on Tuesday, February 20th. They set a “buy” rating and a $30.00 price objective for the company. SunTrust Banks lifted their price target on shares of Verona Pharma plc – American Depositary Share from $26.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, March 26th. Wedbush restated a “buy” rating and issued a $33.00 price objective on shares of Verona Pharma plc – American Depositary Share in a research note on Friday, December 8th. Finally, Stifel Nicolaus set a $25.00 price objective on shares of Verona Pharma plc – American Depositary Share and gave the company a “buy” rating in a research note on Friday, March 2nd. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Verona Pharma plc – American Depositary Share presently has a consensus rating of “Buy” and a consensus target price of $31.17.
VRNA stock opened at $19.98 on Friday. The stock has a market cap of $255.32 and a P/E ratio of -8.29. Verona Pharma plc – American Depositary Share has a 52 week low of $10.44 and a 52 week high of $25.55.
TRADEMARK VIOLATION WARNING: “Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) Getting Somewhat Favorable Press Coverage, Analysis Finds” was reported by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/04/06/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-verona-pharma-plc-american-depositary-share-vrna-share-price/2029454.html.
About Verona Pharma plc – American Depositary Share
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.